Efficacy evaluation of an herbal compound in COVID-19
Phase 2
- Conditions
- COVID-19.COVID-19U07.1
- Registration Number
- IRCT20200323046841N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Hospitalized patients with clinical and CT scan findings strongly suspected of COVID -19
Relative stability in cardiovascular status
Moderate and severe cases
No organ damage
Exclusion Criteria
Pregnant and lactating women
End stage patients
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changing the patient's clinical status in the COVID-19 clinical classification table. Timepoint: Before and after intervention. Method of measurement: Clinical and Paraclinical Indicators in COVID-19 Classification Table.
- Secondary Outcome Measures
Name Time Method Cell blood count. Timepoint: Before and after the intervention. Method of measurement: Cell conuter.;Liver enzymes. Timepoint: Before and after the intervention. Method of measurement: spectrometer.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the active components of Fluherb and their mechanisms against SARS-CoV-2 in IRCT20200323046841N1 Phase II trials?
How does Fluherb in IRCT20200323046841N1 compare to standard-of-care treatments for suspected COVID-19 in Phase II trials?
Which biomarkers and paraclinical parameters predict response to Fluherb in IRCT20200323046841N1 Phase II trials for suspected COVID-19 patients?
What are the safety profiles and adverse event management strategies for Fluherb in IRCT20200323046841N1 Phase II trials for suspected COVID-19?
What other herbal compounds or combination therapies are evaluated with Fluherb in IRCT20200323046841N1 for suspected COVID-19 in Phase II trials?